Martin Nicholas to Glioblastoma
This is a "connection" page, showing publications Martin Nicholas has written about Glioblastoma.
Connection Strength
1.468
-
Bevacizumab for glioblastoma multiforme after traumatic subarachnoid hemorrhage. J Clin Neurosci. 2012 Sep; 19(9):1310-1.
Score: 0.361
-
Molecular heterogeneity in glioblastoma: therapeutic opportunities and challenges. Semin Oncol. 2011 Apr; 38(2):243-53.
Score: 0.332
-
Glioblastoma multiforme: evidence-based approach to therapy. Expert Rev Anticancer Ther. 2007 Dec; 7(12 Suppl):S23-7.
Score: 0.264
-
Association between hospital volume and receipt of treatment and survival in patients with glioblastoma. J Neurooncol. 2017 Dec; 135(3):529-534.
Score: 0.129
-
Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab. Neuro Oncol. 2011 Jun; 13(6):660-8.
Score: 0.084
-
Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study. Oncologist. 2010; 15(12):1329-34.
Score: 0.081
-
Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab. Neuro Oncol. 2011 Jan; 13(1):143-51.
Score: 0.081
-
Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009 Oct 01; 27(28):4733-40.
Score: 0.074
-
Epidermal growth factor receptor - mediated signal transduction in the development and therapy of gliomas. Clin Cancer Res. 2006 Dec 15; 12(24):7261-70.
Score: 0.062